Trastuzumab duocarmazine represents a novel therapeutic approach for the treatment of patients in three different oncology situations: those with HER2+ breast cancer resistant to prior T-DM1, those with HER2-low-expressing breast cancer who currently have no targeted therapy available, and other tumor types overexpressing HER2 [194,195,196]. This evidence concerns the gene ERBB2 and breast cancer.